When training or adequate handling facilities (such as a restraint chute) are lacking, chemical restraint becomes an option for accessing and handling elephants more safely for selected procedures. Many drugs are in use for chemical restraint in elephants (Table 1) but standing sedation is considered to pose a lower risk to captive elephants compared to general anaesthesia. It also allows access to both sides of the animal and, in general, elephant care staff find it more acceptable (Neiffer et al., 2005) . The α 2 -adrenoceptor agonists, such as xylazine and detomidine, in combination with either ketamine or butorphanol have been used for standing sedation in African elephants (Table 1 ) but the use of medetomidine, a more potent and safe α 2 -agonist, has so far only been reported for Asian elephants (Sarma et al., 2002) .
The aim of this study was to define doses of medetomidine and butorphanol combinations to achieve safe and effective standing sedation in captive African elephant bulls of different ages in order to perform procedures like semen collection and transrectal ultrasound examinations.
Twelve captive bulls, 8-30 years old, from four facilities in South Africa were used in the study (Table 2) . Shoulder height was measured during each sedation and mean weight was calculated from this value using four different, previously published formulas (Johnson and Buss, 1965; Hanks, 1972; Laws et al., 1975) . The bulls were sedated once (n=4), or three to four times (n=8) over a period of 3 years. All procedures were carried out in accordance with the Animal Use and Care Committee of the University of Pretoria (permit V016-12; 24 April 2012). A combination of medetomidine (20 mg/mL, Kyron Laboratories) and butorphanol (50 mg/mL, Kyron Laboratories) were drawn up into one syringe. Males were either guided into a restraint chute or pen system, where they were injected IM by hand, or were darted while free-standing outside and only restrained thereafter.
When the tip of the elephant's trunk was fully relaxed and resting on the ground, attempts to access the animal began. If, after 30 min, the elephant was still responsive to handling of the tail, or the trunk was not permanently resting on the ground, or leg movements were present, an IV or IM top-up was given (Table 2) . During the last round of sedations (n=8) 1000 to 2000 IU hyaluronidase (Hylase, 5000 IU per vial, Kyron Laboratories) were added to the cocktail to promote rapid drug resorption. For reversal of the sedations, naltrexone (Trexonil, 50 mg/mL, Wildlife Pharmaceuticals) and atipamezole (Antisedan, 5 mg/mL, Zoetis) were administered IM or partially IV in separate syringes. Table 2 shows the drugs and dosages used to sedate and reverse each of the 12 bulls treated 1-4 times. The mean intervals from injection until the first observed effect were 7.7 min (5-12 min) without hyaluronidase and 12 min (5-30 min) after the addition of hyaluronidase. Average time to full sedation was 25.5 min (10-52 min) without
hyaluronidase. The addition of hyaluronidase significantly reduced the time to full sedation to 16.5 min (12-33 min). The statistical analysis was performed using GraphPad InStat Version 3 software for a paired t test (P=0.024; df=7; n=8 bulls).
For 11 sedations in seven bulls, a top-up dose was needed 25-30 min after administration of the initial bolus (Table 2 ). Mean total duration of sedation required for all procedures to be completed was 75 ± 20 min (48-110 min). In a single case, the youngest elephant (number 2) partially collapsed onto his carpal joints about 85 min after administration of the sedative drugs ( Table 2 ). The drug was immediately reversed with 25 mg atipamezole and 50 mg naltrexone IV and an additional 100 mg naltrexone IM. He regained his footing rapidly and was fully conscious after 3 min.
All sedations were partially or completely reversed with IM atipamezole and naltrexone (Table 2) . On seven occasions, one-third of the dose was given IV and the remainder given IM. In both cases, full recovery was achieved quickly and took on average 7 ± SD 4 min (2.5-18.0 min).
The results show that the combination of medetomidine ( was required for each of the 11 procedures. Induction times were significantly reduced when 1000-2000 IU hyaluronidase were added to the drug combination. This enzyme is used to facilitate drug resorption during wildlife immobilizations (Morton and Kock, 1991) .
Medetomidine is the most potent of the α 2 -adrenoreceptor agonist family with more specific actions on receptors associated with sedation and analgesia (Fowler and Mikota, 2006) .
Previously, however, only detomidine in combination with butorphanol in a 1:1 ratio has been described for African elephants (Neiffer et al., 2005 ; Table 1 ).
The mean dose of medetomidine administered in combination with butorphanol in this study was almost twice the dose used for captive Asian elephants (Sarma et al., 2002) in which acceptable standing sedation was achieved using medetomidine alone. Asian elephants appear to be far more sensitive to the α 2 -agonists. For example, the recommended dose for detomidine in Asian elephants is 0.0055 mg/kg (Fowler and Mikota, 2006) , whereas African elephants require 0.013-0.02 mg/kg (Neiffer et al., 2005 ; Table 1 ).
All of our elephants were able to walk out of the restraint pen or chute within 10-15 min after administration of the antidotes. The reversibility of both drugs used in the present study is a great advantage over drug combinations that include ketamine or azaperone, which have no reversal agent. Adverse gastrointestinal side effects (such as bloat or mild colic), as have been described after similar sedations in African elephants (Neiffer et al., 2005) , were not seen. The only side effect we observed was increased salivation in all bulls.
In conclusion, this study determined an effective and fully reversible combination dose of medetomidine and butorphanol required to achieve standing sedation in African elephant bulls. The inclusion of hyaluronidase in the sedative cocktail significantly reduced the induction time.
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